[{"id":"ef3ee7ea-e266-49a7-bd2d-0c9eccee4dcb","acronym":"EvoPAR-PR02","url":"https://clinicaltrials.gov/study/NCT06952803","created_at":"2025-06-07T14:51:41.431Z","updated_at":"2025-06-07T14:51:41.431Z","phase":"Phase 3","brief_title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","source_id_and_acronym":"NCT06952803 - EvoPAR-PR02","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • saruparib (AZD5305)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 05/30/2025","start_date":" 05/30/2025","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 04/30/2036","study_completion_date":" 04/30/2036","last_update_posted":"2025-05-30"},{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"62aca2f8-43be-49bc-a240-562947c24958","acronym":"D5330C00004","url":"https://clinicaltrials.gov/study/NCT02264678","created_at":"2021-01-17T17:33:57.498Z","updated_at":"2024-07-02T16:35:02.492Z","phase":"Phase 1/2","brief_title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","source_id_and_acronym":"NCT02264678 - D5330C00004","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation","tags":["HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • ceralasertib (AZD6738) • saruparib (AZD5305)"],"overall_status":"Recruiting","enrollment":" Enrollment 466","initiation":"Initiation: 10/31/2014","start_date":" 10/31/2014","primary_txt":" Primary completion: 08/05/2026","primary_completion_date":" 08/05/2026","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2024-05-21"}]